AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03280745
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
Trial: NCT02227368
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
Trial: NCT01160380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
Trial: NCT00300846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
Trial: NCT04136262
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 10 mg per week for 24 weeks.
Trial: NCT01663857
Drug: LY2228820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT01663857
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT01421147
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT02751619
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
Trial: NCT00034047
Drug: Chinese Products
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05229627
Drug: ATX
RxNorm normalized name: Diatx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the drug would be prescribed to patients without any contraindication
Trial: NCT00063297
Drug: R209130
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03307837
Drug: CA-008
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local administration during surgery
Trial: NCT03307837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local administration during surgery
Trial: NCT04100655
Drug: 17-ß estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
Trial: NCT02732015
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01156883
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01156883
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01156883
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01156883
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00943501
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
Trial: NCT00943501
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
Trial: NCT04544163
Drug: Magnesium sulfate- Fentanyl
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug administration before intubation
Trial: NCT04544163
Drug: Fentanyl 4Mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug administration with induction of anesthesia
Trial: NCT04544163
Drug: Fentanyl 2Mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug administration with induction of anesthesia
Trial: NCT02301845
Drug: Diatoms Shells
RxNorm normalized name: egg shell membrane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instillation of suspended diatom shells - 10 mg q12h
Trial: NCT02171832
Drug: BI 1744 CL, low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02171832
Drug: BI 1744 CL, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03664921
Drug: Omnitram Oral Tablet
RxNorm normalized name: Orenitram Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered three times daily for 28 consecutive days.
Trial: NCT03664921
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered three times daily for 28 consecutive days.
Trial: NCT02362425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00824707
Drug: conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional therapy including protecting the liver function, anti-tumor and so on
Trial: NCT00525876
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Matched Donors:~750 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m\^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
Trial: NCT00596453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice a day for 14 days
Trial: NCT01313221
Drug: Topical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~* hydrocortisone 2.5%~* betamethasone valerate 0.1%~* betamethasone dipropionate 0.05%~* clobetasol 0.05%~* calcitriol~* calcipotriol plus betamethsone dipropionate 0.05%
Trial: NCT00719394
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03231137
Drug: ATV gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin gel
Trial: NCT00333632
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02844894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT01031017
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02217800
Drug: DG3173
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
Trial: NCT01754766
Drug: AGN-229666
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of AGN-229666 into each eye on Day 1 and Day 15.
Trial: NCT01967979
Drug: RO5285119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, alone and after repeated administration of itraconazole or fluoxetine
Trial: NCT01967979
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple doses
Trial: NCT00433017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Trial: NCT01793350
Drug: BC-DN-01 topically applied cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
Trial: NCT03627715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT04112550
Drug: Oxycodone-Acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDA approved medication to treat pain
Trial: NCT03972501
Drug: AZR-MD-001 Active Dose
RxNorm normalized name: eptacog alfa activated 0.001 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZR-MD-001 is an ophthalmic ointment
Trial: NCT01342445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01873157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11.
Trial: NCT04193553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered continuously but patient's follow-up visits will be scheduled monthly.~The starting dose of study treatment is 24mg, once daily, at the same time. Recommendations for placebo dose reductions are the same as for Lenvatinib. If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.~Study treatments will be continued until a treatment discontinuation criteria is met.~In case disease progression, patients in control arm could switch in the Lenvatinib + BSC arm.
Trial: NCT00802672
Drug: Loprox Cream 0.77%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream
Trial: NCT00802672
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream
Trial: NCT00394394
Drug: Amiloride 2,5/d or Enalapril/d 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01319487
Drug: Placebo Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Eye Drops self-administered in the study eye during the treatment period
Trial: NCT00214656
Drug: Recombinant Activated Factor VII
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01241331
Drug: BLI1100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI110 topical cream
Trial: NCT01241331
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle topical cream
Trial: NCT02081014
Drug: G-Pen Mini™ (glucagon injection)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stable, pre-mixed, liquid glucagon for subcutaneous injection
Trial: NCT02875873
Drug: Plasma-Lyte
RxNorm normalized name: Plasma-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma-Lyte will be used for fluid expansion and maintenance
Trial: NCT02875873
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% will be used for fluid expansion and maintenance
Trial: NCT00176514
Drug: Administration of the antineoplastic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03033160
Drug: Estradiol Ring
RxNorm normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06365190
Drug: Pharmacotherapy（antiparkinsonian drugs）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Parkinson's disease drugs include compound levodopa, dopamine receptor agonists, monoamine oxidase type B inhibitors, catechol-O-methyl transferase inhibitors, etc. Take dopaminergic agents regularly, with follow-up every 8 weeks including medication guidance and symptom assessment
Trial: NCT02799888
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.
Trial: NCT00514982
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic Corticosteroid used to treat inflammatory conditions.
Trial: NCT01548768
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi.
Trial: NCT01548768
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
Trial: NCT00290693
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
Trial: NCT01515566
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
Trial: NCT00003902
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00560703
Drug: COL-101 (doxycycline, USP) capsules
RxNorm normalized name: Doxycycline Capsules
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg, once per day for 84 days
Trial: NCT00560703
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar capsule
Trial: NCT00258193
Drug: MD-1100 Acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03927326
Drug: Exparel 266 MG Per 20 ML Injection
RxNorm normalized name: Exparel 266 MG per 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine
Trial: NCT04394663
Drug: Standard IV PPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 8mg/hour IV continuous drip will be prescribed for 72 hours after randomization
Trial: NCT01979601
Drug: LGT209
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg lyophilized powder in glass vial
Trial: NCT01979601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03421275
Drug: Fentanyl Citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous fentanyl given intranasally
Trial: NCT02265939
Drug: NPO-13
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03616392
Drug: D308, CKD-501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. D308~2. CKD-501: Lobeglitazone sulfate 0.5mg
Trial: NCT00647036
Drug: Dipeptiven (L-glutamine- Lalanine)
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6g/kg/day
Trial: NCT02540161
Drug: Sym004 - 18 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sym004 was dosed at 18 mg/kg intravenously every two weeks.
Trial: NCT01043484
Drug: Capecitabine + Radiotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
Trial: NCT04231968
Drug: AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK0529 capsule will be orally administered at the twice-daily dosing levels of 10 mg, 20 mg, or 40 mg for five days based on the patient's weight.
Trial: NCT04231968
Drug: Matching placebo of AK0529
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsule was made with the same smell and appearance as AK0529 but without the active ingredients and will be orally administered per the same treatment schedule as those in the experimental arm.
Trial: NCT02324699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03183479
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL normal saline will be administered to patients in control group as placebo
Trial: NCT01693185
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous infusion 0.4 mcg/kg/min
Trial: NCT01693185
Drug: placebo (for meperidine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline mimic meperidine injection
Trial: NCT01401543
Drug: LY2452473
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00897871
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01636089
Drug: bicarbonates
RxNorm normalized name: BICARBONATES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium bicarbonates 1,4%
Trial: NCT00003974
Drug: DetoxPC
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003974
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003974
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01887288
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 650 mg/m\^2 PO b.i.d.
Trial: NCT00556257
Drug: CP-690-,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
Trial: NCT01717157
Drug: Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
Trial: NCT02915250
Drug: Humalog® Mix25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Humalog® Mix25
Trial: NCT02915250
Drug: Lantus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of Lantus®
Trial: NCT00039481
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00039481
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00370435
Drug: GW274150
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02178358
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02178358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00479115
Drug: AMD3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
Trial: NCT00264290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo designed to resemble Valganciclovir
Trial: NCT02779075
Drug: Exendin-9,39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
Trial: NCT00914498
Drug: Local, pre-incisional injection of 20 ml 1% xylocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local, pre-incisional injection of 20 ml 1% xylocaine
Trial: NCT00408187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00057005
Drug: CAMPATH-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-8 through Day-6 according to institutional SOPs
Trial: NCT00057005
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day-7 through Day-6 45 mg/kg
Trial: NCT00391807
Drug: Norethindrone acetate/ethinyl estradiol
RxNorm normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet per day
Trial: NCT01110226
Drug: KML-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 15mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off.
Trial: NCT02574819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
Trial: NCT01917695
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
Trial: NCT05103306
Drug: INS
RxNorm normalized name: mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal insulin add on the background OADs